BIOLASE ANNOUNCES DISTRIBUTION OF SERIES I PREFERRED STOCK TO HOLDERS OF ITS COMMON STOCK Jun 05, 2023 5:30pm EDT
BIOLASE Takes Steps to Improve Operating Efficiency as the Company Pursues Sales and Profitability Goals Jun 05, 2023 7:14am EDT
BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants May 26, 2023 11:25am EDT
BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants May 24, 2023 9:14am EDT
BIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023 May 11, 2023 4:21pm EDT
BIOLASE DELIVERS 24% REVENUE GROWTH IN 2022 AS GO-TO-MARKET STRATEGIES GAIN MOMENTUM; GUIDES FOR AT LEAST 25% REVENUE GROWTH AND PROFITABILITY IN 2023 Mar 28, 2023 4:05pm EDT
BIOLASE GATHERS KEY OPINION LEADERS AND DENTAL CLINICIANS TO HIGHLIGHT TONGUE-TIE TREATMENT BEST PRACTICES Mar 14, 2023 6:30am EDT
BIOLASE TO REPORT FOURTH QUARTER AND FULL YEAR 2022 RESULTS ON MARCH 28, 2023 Mar 13, 2023 6:30am EDT
